Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

Trial Details

NCT ID

NCT04771572

Phase

PHASE1

Sponsor

Newave Pharmaceutical Inc

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

LP-118

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005
Boston, Massachusetts, United States|42.35843,-71.05977
Chapel Hill, North Carolina, United States|35.9132,-79.05584
Cincinnati, Ohio, United States|39.12711,-84.51439
Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

Male or female subjects, ≥ 18 years of age at the time of Screening with the following exception as outlined below:
For T cell and B cell ALL subjects with age between 13 - 18 years, their body weight shall be ≥ 40 kg.
Eligible subject must have an advanced hematologic malignancy including:
Relapsed or refractory low risk tumor lysis CLL/SLL subjects (ALC \< 25 x 109 cells/L and all lymph nodes \< 5 cm) who have received at least two p…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →